SecBot SecBot
8-K ·Filed May 6, 2026

PODD

INSULET CORP
BULLISH
Impact 7/10
Horizondays Processed6mo ago SEC0001145197-26-000100
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The Q1 beat and FY guidance raise confirm strong execution and accelerating international adoption. Watch for the broader Omnipod 5 algorithm launch and EVOLVE pivotal study enrollment as catalysts. The medical device correction is a modest overhang but appears contained.

DirectionBullish
Confidencehigh
Horizondays

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$150.52
T+0 close · May 6, 2026 · via day close
Latest settled
+10.07%
T+60 · $165.68
Vs SPY
+9.00%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 6 $150.52entry
  2. T+1 · 6mo ago +6.05%α +6.38% · $159.62
  3. T+5 · 6mo ago +5.20%α +4.07% · $158.35
  4. T+20 · 6mo ago −4.80%α −7.58% · $143.30
  5. T+60 · 4mo ago +10.07%α +9.00% · $165.68

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Insulet reported Q1 2026 revenue of $761.7M (+33.9% YoY, +30.1% cc), exceeding the high end of its 25%-27% cc guidance, and GAAP diluted EPS of $1.30 (vs $0.50 YoY). The company raised its full-year 2026 total revenue growth guidance to 21%-23% cc (from 20%-22% cc), driven by strong Omnipod 5 adoption and international expansion. The beat and guidance raise are positive, but the stock has historically not reacted well to earnings beats, and the voluntary medical device correction in March 2026 introduces a modest headwind.

Key Financial Metrics

EPS
$1.30
est $1.19 · +9.2%
Revenue
$761.7M
est $730.1M · +4.3% · +33.9% YoY
Rating
strong beat
Guidance
21%-23% constant currency growth (FY 2026)
raised
Free Cash Flow
$89.5M
Gross Margin
69.5%

Key Facts

  • Q1 2026 revenue of $761.7M (+33.9% YoY, +30.1% cc) exceeded the high end of 25%-27% cc guidance
  • Total Omnipod revenue of $758.4M (+36.9% YoY, +33.0% cc); International Omnipod revenue surged 59.4% (+45.2% cc)
  • GAAP diluted EPS of $1.30 vs $0.50 YoY; Adjusted diluted EPS of $1.42 vs $1.02 YoY (+39.7%)
  • Raised FY 2026 total revenue growth guidance to 21%-23% cc (from prior 20%-22% cc); maintained 100bps adjusted operating margin expansion and 25% adjusted EPS growth targets
  • Voluntary medical device correction in March 2026 incurred $11.7M in estimated warranty costs (included in cost of revenue)
  • Repurchased 1.25 million shares of common stock in Q1
  • Operating cash flow of $113.8M vs $63.8M YoY; Free cash flow of $89.5M vs $51.6M YoY

Financial Impact

Revenue beat of ~$31.6M vs consensus ($761.7M actual vs $730.1M est); GAAP EPS beat of $0.11 vs consensus ($1.30 actual vs $1.19 est)

revenueepsoperating marginfree cash flow

Risk Factors

  • Voluntary medical device correction could lead to further warranty costs or regulatory scrutiny
  • International growth faces currency headwinds (14.2% currency impact in Q1) and geopolitical risks (Iran conflict mentioned)
  • Competitive pressure from other AID systems (Tandem, Medtronic) could slow market share gains
  • Stock has historically underperformed after earnings beats, suggesting market may be pricing in higher expectations

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
91% bullish (34 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001145197-26-000100
Document: podd-20260506.htm0001145197-26-000100
Document: 0001145197-26-000100-index-headers.html0001145197-26-000100
Document: 0001145197-26-000100-index.html0001145197-26-000100
Document: 0001145197-26-000100.txt0001145197-26-000100
8-K Data (Synthetic)0001145197-26-000100

Track record

11 reports on PODD

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry price pending
  2. Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $152.48 Now $145.29 −4.72% settles Feb 11
  3. Nov 4, 202612d ago 8-K Bullish 6/10 Entry $165.02 Now $145.29 −11.96% settles Feb 2
  4. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $148.93 Now $145.29 −2.44% settles Jan 26
  5. Oct 23, 202624d ago Institutional Cluster Neutral 3/10 Entry $149.01 Now $145.29 −2.50% settles Jan 21
  6. Sep 21, 20268w ago 8-K Bullish 6/10 Entry $139.38 Now $145.29 +4.24% settles Dec 16
  7. Aug 5, 202614w ago 8-K Mixed 5/10 Entry $132.30 to $152.50 Now $145.29 +9.82% ▲ +15.26% +15.32% vs SPY
  8. Jul 24, 202616w ago Institutional Cluster Bearish 5/10 Entry $163.26 to $141.96 Now $145.29 +11.01% ▲ +13.05% +16.77% vs SPY
  9. May 28, 202624w ago Court Ruling Bearish 7/10 Entry $141.98 to $147.92 Now $145.29 −2.33% ▼ −4.18% −2.71% vs SPY
  10. May 6, 202627w ago 8-K Bullish 7/10 Viewing Entry $150.52 to $165.68 Now $145.29 −3.48% ▲ +10.07% +9.00% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens Wed (11h 13m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 6, 2026